Found 13 matching trials
Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors PHASE1 Primary Objective:
\- To determine a dose of SAR240550 to be further studi...
Show More Location
Sanofi-Aventis Investigational Site Number 392001
Learn More & Join Trial
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors PHASE1 Primary Objective:
* To assess the safety and the maximum tolerated dose(M...
Show More Location
Investigational Site Number 840002
Learn More & Join Trial
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer PHASE2 The purpose of this study is to evaluate the effect of BSI-201 on the objec...
Show More Location
Massachusetts Ceneral Hospital
Learn More & Join Trial
A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer PHASE2 The purpose of this clinical trial was to determine whether combining inipa...
Show More Learn More & Join Trial
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer PHASE2 The purpose of this study is to evaluate the effect of BSI-201 on the objec...
Show More Location
Massachusetts Ceneral Hospital
Learn More & Join Trial
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) PHASE3 To evaluate the overall survival (OS) of patients with advanced squamous ce...
Show More Location
Investigational Site Number 840306
Learn More & Join Trial
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer PHASE3 The goal of this study was to determine the effect on overall survival and ...
Show More Learn More & Join Trial
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer N/A The following trial is designed to offer pre-approval drug access to inipar...
Show More Status
No Longer Available
Location
Multiple Locations
Learn More & Join Trial
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer PHASE2 This study will investigate whether the neoadjuvant combination of gemcitab...
Show More Location
Stanford Comprehensive Cancer Center
Learn More & Join Trial
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial PHASE3 The purpose of this study is to assess the safety and tolerability of inipa...
Show More Location
Investigational Site Number 840013
Learn More & Join Trial